EGFR and non-small cell lung carcinoma: Amivantamab is a bispecific antibody that targets EGFR and mesenchymal‐epithelial transition (MET) receptor,[392] which is the first approved targeted therapy for advanced NSCLC patients with an EGFR exon 20 insertion mutation in 2021.